CGTX News - Candlesense

Cognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer’s Disease Reaches 75% Enrollment Target

(NASDAQ:CGTX) PURCHASE, N.Y., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neur...

How does CT1812's mechanism and trial design compare with other late‑stage Alzheimer’s candidates, and what could that mean for market positioning if the study succeeds? What are the primary risks that could delay full enrollment or compromise the integrity of the START study results? How will the 75% enrollment milestone affect CGTX's near‑term share price and trading volume?

Clinical trials

11 days ago

Cognition Therapeutics Closes $30 Million Registered Direct Offering to Two New Fundamental Institutional Investors, Including a Preeminent Global Investment Firm to Support Phase 3 Development of Zervimesine (CT1812)

(NASDAQ:CGTX) PURCHASE, N.Y., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat ...

Who are the two new fundamental institutional investors and does their participation signal increased credibility for Cognition’s pipeline? What are the expected timelines and milestones for Phase 3 of Zervimesine (CT1812) and how might they impact the stock? How will the $30 million capital raise affect dilution and future earnings per share?

Financing

12 days ago

Cognition Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

PURCHASE, N.Y., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerati...

How might the regained compliance affect the stock's eligibility for inclusion in index funds and its overall liquidity? Is there a risk that the company's bid price could fall below the $1 threshold again, prompting another delisting warning? Will the reinstatement of Nasdaq compliance trigger a short‑cover rally or increased buying pressure on CGTX?

Regulation

19 days ago